Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections
NCT04859621Phase 2Recruiting
- Sponsor
- Zensun
- Start
- May 2021
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vitamin d in urinary tract infection (UTI) (3 arms), sponsored by Zensun. Primary endpoint: UTI recurrent incidence in 48 weeks. Started May 2021; status: recruiting.
02
Drugs
vitamin d
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT04859621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859621.